Skip to main content

Paradigm Genetics Revenues Up, Losses Down in Q4

NEW YORK, Feb. 20 (GenomeWeb News) - Paradigm Genetics yesterday reported improved revenues and considerably narrowed losses for the fourth quarter of 2003.

Revenues increased to $5.5 million, from $1.9 million during the fourth quarter of 2002.

R&D expenses for the quarter increased slightly to $6 million, from $5.7 million the year before.

Net losses amounted to $2.2 million, or $.07 per share, down from $9.3 million, or $.29 per share, during the year-ago period.

As of Dec. 31, Paradigm had cash, cash equivalents, and short-term investments of $10.2 million.

Click  here for the full earnings report.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.